The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Choi, Jong Hyun; Choi, Juwhan; Chung, Sang Mi; Oh, Jee Youn; Lee, Young Seok; Min, Kyung Hoon; Hur, Gyu Young; Shim, Jae Jeong; Kang, Kyung Ho; Lee, Hyun Kyung; Lee, Sung Yong

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Recommendations

Search

Type: Academic journal

Author: Choi, Jong Hyun (Department of Internal Medicine, Korea University Guro Hospital) Choi, Juwhan (Department of Internal Medicine, Korea University Guro Hospital) Chung, Sang Mi (Department of Internal Medicine, Korea University Guro Hospital) Oh, Jee Youn (Department of Internal Medicine, Korea University Guro Hospital)

Journal: The Korean Academy of Tuberculosis and Respiratory Diseases Tuberculosis and Respiratory Diseases 결핵 및 호흡기 질환 제82권 제3호 KCI Accredited Journals SCOPUS

Published: 2019.1

Pages: 211 - 216 (6page)

Usage

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Abstract· Keywords

Report Errors

Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel $25mg/m^2$ on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.

#Carcinoma, Non-Small-Cell Lung #Chemotherapy #Docetaxel #Treatment Outcome #Safety #Therapeutics #Aged #Lung Neoplasms #Carcinoma, Squamous Cell

No content found

References (0)

Add References

If the reference is being serviced by DBpia, please register through [Add Reference]

Recommendations

It is an article recommended by DBpia according to the article similarity. Check out the related articles!